A boutique venture capital firm founded in 2015 in Hong Kong is currently investing from its $100M fund in early stage cross-border technology companies in TMT and MedTech. The firm generally participates in Series A rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing, and is actively seeking new opportunities from across the world with a focus on companies in China, U.S. and Europe. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand aboard. The firm expects to make 8 new investments in the next 6 months.
The firm is most interested in medical devices such as minimally invasive surgical instruments, artificial intelligence and robots, diagnostic tools; and mobile health innovations. The firm is seeking innovations that have completed prototype. The firm would also consider therapeutics for large disease markets with a special interest in immunotherapy and cell therapy.
The firm is in search of ambitious companies with strong, experienced management teams. The firm can work with incomplete teams and contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request right of priority distribution rights or negotiation rights in China.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org